SCA
ALNY icon

Signpost Capital Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Signpost Capital Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-46,000
Closed -$3.12M – 10
2016
Q3 		$3.12M Buy
+46,000
New +$3.25M 2.62% 10

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Signpost Capital Advisors's ALNY Position: Q1 2017 in Review

Signpost Capital Advisors reduced its Alnylam Pharmaceuticals (ALNY) stake by 50% in Q1 2017, selling an estimated $766K and leaving 16,485 shares worth $845K. The position accounts for 2.47% of the portfolio, ranked #7.

Signpost Capital Advisors first reported a position in ALNY in Q1 2016 and has held it in 5 quarters since. The position peaked at $2.33M in Q3 2016. 199 funds tracked by Wall St. Rank hold ALNY as of Q1 2017.

  • Signpost Capital Advisors held 16,485 shares of Alnylam Pharmaceuticals worth $845K as of Q1 2017.
  • Signpost Capital Advisors sold 16,580 Alnylam Pharmaceuticals shares in Q1 2017, an estimated $766K.
  • Alnylam Pharmaceuticals made up 2.47% of Signpost Capital Advisors's portfolio in Q1 2017, its #7 holding.
  • Signpost Capital Advisors first reported a position in Alnylam Pharmaceuticals in Q1 2016 and has held it in 5 quarters since.
  • Signpost Capital Advisors's Alnylam Pharmaceuticals position peaked at $2.33M in Q3 2016.
  • 199 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2017.

Based on Signpost Capital Advisors's 13F filing for Q1 2017, filed 1 May 2017.